Last reviewed · How we verify
RHZE
At a glance
| Generic name | RHZE |
|---|---|
| Also known as | Rifafour, Rimstar |
| Sponsor | Sequella, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression (PHASE3)
- B-PaLMZ for TB Meningitis (PHASE2)
- Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study (PHASE2)
- High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis (PHASE2)
- Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease (PHASE3)
- Azacytidine During Anti-tuberculosis Therapy (PHASE1, PHASE2)
- Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia (NA)
- Latency in Pulmonary Tuberculosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RHZE CI brief — competitive landscape report
- RHZE updates RSS · CI watch RSS
- Sequella, Inc. portfolio CI